Form 10-Q PROVECTUS BIOPHARMACEUTI For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Provectus Biopharma (PVCT) Reports Q2 Loss of $0.02/Share
August 11, 2016 9:29 AM EDTProvectus Biopharma (NYSE: PVCT) reported Q2 EPS of ($0.02), versus ($0.02) reported last year.
Our cash and cash equivalents were $4,891,313 at June 30, 2016, compared with $9,760,997 at March 31, 2016.
For earnings history and earnings-related data on Provectus Biopharma (PVCT) click here.
... More